Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports ...
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System AtrophyBOSTON, May 14 ...
Tiziana Life Sciences reported encouraging brain inflammation findings in its MSA study, strengthening attention on ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
MedPage Today on MSN
Is Pure Autonomic Failure a Warning Sign for Parkinson's? What a New Study Shows.
High conversion rates to Parkinson's, dementia with Lewy bodies, or multiple system atroph ...
Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale ...
Detailed price information for Alterity Therapeutics Ltd (PRNAF) from The Globe and Mail including charting and trades.
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System AtrophyBOSTON, May 14 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results